Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;10(1):129-37.
doi: 10.4161/hv.26269. Epub 2013 Sep 4.

Combined Hexavalent Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-inactivated poliovirus-Haemophilus Influenzae Type B Vaccine; Infanrix™ Hexa: Twelve Years of Experience in Italy

Affiliations
Free PMC article
Review

Combined Hexavalent Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-inactivated poliovirus-Haemophilus Influenzae Type B Vaccine; Infanrix™ Hexa: Twelve Years of Experience in Italy

Vincenzo Baldo et al. Hum Vaccin Immunother. .
Free PMC article

Abstract

Infant vaccination using 2-dose priming at 3 and 5 mo of age with a booster at 11-12 mo of age was pioneered in Italy. The 3-5-11 schedule is now used in a growing number of European countries. Infanrix™ hexa (DTPa-HBV-IPV/Hib, GlaxoSmithKline Vaccines) was first licensed for use in 2000 and has been the only pediatric hexavalent vaccine available since 2005. We reviewed available clinical trial data describing the immunogenicity of DTPa-HBV-IPV/Hib when administered at 3, 5, and 11 mo of age, and conducted an analysis of safety using global and Italian post-marketing surveillance data. In Italy, DTPa-HBV-IPV/Hib has a demonstrated safety record extending over a decade of use, it has been associated with record levels of vaccine coverage, and with sustained disease control in vaccinated cohorts. Hexavalent vaccines will continue to contribute to high vaccine coverage in Italy and across Europe.

Keywords: Italy; booster vaccination; combination vaccines; hexavalent vaccine; immunogenicity; primary vaccination; safety.

Figures

None
Figure 1.Haemophilus influenzae invasive disease in children <5 y of age: Italy 1994–2012. Adapted from publically available data reports of Istituto Superiore di Sanità-Roma, accessed at http://www.simi.iss.it/files/Report_MBI.pdf and http://www.simi.iss.it/files/Report_meningiti_1994-2006.pdf April 2013). *partial data.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

References

    1. Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26:496–500. doi: 10.1097/INF.0b013e31805d7f17. - DOI - PubMed
    1. Happe LE, Lunacsek OE, Kruzikas DT, Marshall GS. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population. Pediatr Infect Dis J. 2009;28:98–101. doi: 10.1097/INF.0b013e318187d047. - DOI - PubMed
    1. Happe LE, Lunacsek OE, Marshall GS, Lewis T, Spencer S. Combination vaccine use and vaccination quality in a managed care population. Am J Manag Care. 2007;13:506–12. - PubMed
    1. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt H-J, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25:507–12. doi: 10.1097/01.inf.0000222413.47344.23. - DOI - PubMed
    1. Infanrix hexa product information. 2011 Sep 14 [cited 2013 Feb 18]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000296/human_med_000833.jsp&mid=WC0b01ac058001d124

Publication types

MeSH terms

Substances

Feedback